Notable Labs, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col

The ongoing reckoning among biopharmaceutical companies that are running out of cash and unable to raise new funds – either because of a lack of near-term upcoming milestones or missed milestones – is

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sanofi Hopes Owkin Can Aid Oncology Dis